A complete AI solution to support the early detection, diagnosis, and management of major neurological disorders

We're the only company offering a complete AI solution for entire patient care pathways of major neurological disorders.

How does cNeuro® work?

Comprehensive patient management is possible because we have connected our cNeuro® cMRI™ and cNeuro cDSI™ applications with multiple external data sources within the cloud-based cNeuro platform.

cMRI, which can also be used as a standalone application, provides fully automated brain MRI quantification.

cDSI combines this imaging data with other key patient data and AI methods to support diagnosis, testing decisions, and prediction of disease progression.

cNeuro® cMRI

Fully automated MRI quantification

Validated cMRI imaging biomarkers are transferred

cNeuro® cDSI

AI-supported differential diagnosis and prediction of neurodegenerative diseases

Clinical data and lab results are transferred

External Data

Key patient data are combined from multiple sources

cNeuro® cMRI

Fully automated MRI quantification

Validated cMRI imaging biomarkers are transferred

cNeuro® cDSI

AI-supported differential diagnosis and prediction of neurodegenerative diseases

Clinical data and lab results are transferred

External Data

Key patient data are combined from multiple sources

About the cNeuro® Products

Collaboration between disciplines results in improved patient care. cNeuro combines cMRI and cDSI in a single platform to make it easier for radiologists and clinicians to communicate, even between different organizations. The high-quality reports provide more than just the test results — they put them in context of all the patient data to provide clinicians with the insight they need for confident, reliable decisions.

cNeuro® cMRI

With fully automated detection and reporting of abnormalities on brain MRI, radiologists can:

Evaluate atrophy and other brain structural changes.

Quantify white matter abnormalities.

Compare the results to reference data.

cNeuro® cDSI

With access to a comprehensive, intuitive clinical decision support system that combines imaging information with a wide range of other patient data, neurologists can evaluate an individual patient’s disease state and:

Review patient’s data, with comparisons to a large set of data from previous patients.

Provide their patients with an earlier, more confident diagnosis and predict disease progression.

Make data-driven decisions about whether additional testing is necessary.

Gain a holistic and intuitive view of the patient’s data using our patented disease state fingerprint technology.

Get the most out of our AI tools with reports that support diagnoses

The new Dementia Differential Analysis report is based on MRI data only, using our cDSI application’s proprietary machine learning method that measures the similarity of disease-specific imaging biomarker values from the patient to those from 2,000+ patients with a confirmed neurodegenerative disease. Supported diagnoses include Alzheimer’s disease, frontotemporal dementia, vascular dementia, and cognitively normal.

cNeuro has become an indispensable tool for us [in the memory clinic], as the quantified information helps with differential diagnosis and assessing whether cognitive issues are due to dementia.

Marie RydénGeriatrician and Head Clinician at the Memory Clinic, Karolinska University Hospital

“cNeuro is a very useful tool for me on a daily basis, and we use it for all dementia investigations and for some MS patients. I find cNeuro particularly useful in intermediate situations, where I am in doubt of the existence or type of atrophy, and for assessing follow-up scans. cNeuro usage and reporting are also highly appreciated by my referring physicians.”

Marian Simko, M.D.Head Radiologist of CIMF, Fribourg, Switzerland

“cNeuro allows us to not only get quantitative information when reading the scans but also to share the imaging information with the referring organization, enabling them to combine imaging data with clinical data in cNeuro^®️ cDSI.”

Thomas Lindahl MD, PhDMedical Director, Unilabs Sweden